CAN-PDP

CAN-PDP: CANnabidiol for Parkinson’s Disease Psychosis 

CAN-PDP is a phase 2b, randomised, double-blind clinical trial seeking to determine if Cannabidiol (CBD) is safe and well tolerated in people with Parkinson’s Disease Psychosis. The study is investigating whether CBD can reduce the severity of hallucinations, delusions and psychosis symptoms in people with Parkinson’s disease and Parkinson’s Disease Dementia.  CBD is the non-addictive component of the cannabis plant that has potential antipsychotic properties. We have recently opened as a site in NHS Lothian and are looking for people with PD and PDD who report visual hallucinations or delusions (with or without insight) for at least 1 month.

If deemed eligible to be included in CAN-PDP, there ill be 6 in-person visits to the Clinical Research Facility at the Western General Hospital. After initial screening, participants will be randomised to receive Cannabidiol 400mg/day for the first 6 weeks, then increased to 800 mg/day for the last 6 weeks or matched placebo for a total of 12 weeks study period.

Brief eligibility is:

• Diagnosis of idiopathic Parkinson’s disease or Parkinson’s disease dementia. 
• Patient or carer reports visual hallucinations or delusions for at least 1 month with no other obvious cause (e.g., infection, dopamine agonist). 
• Other eligibility criteria apply.  
• The research team will review and discuss with the patient and feedback. 
• Participants require a carer or study partner. 

For further information regarding the study please see the trial website from the study team at King’s College London.